Spun off from Emory University, RayBiotech is organized around providing cutting-edge array technologies for the discovery of disease-related protein biomarkers and key factors, the identification of new drug targets, and the advancement of personalized medicine. Completion of the human genome sequence has enabled researchers to analyze the expression of a myriad of disease-related genes; however, many diseases result from abnormal protein expression, post-translational modification, or interaction with other biomolecules. Thus, an understanding of disease states cannot be obtained from genomic research alone. Ultimately, efficient, high-throughput protein analysis offers the most promising approach to understanding and treating disease. From the founding of the firm, RayBiotech addressed this need by introducing the first commercially available cytokine antibody array. The firm's product lines have expanded to include hundreds of arrays and immunoassays for efficient analysis of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transductiom with RayBiotech's comprehensive service programs include Array Testing Services, Biomarker Discovery, Peptoid Discovery, and Custom Assay Development.
